Biomarker analysis of cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric and oesophago-gastric junction cancer: results from a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO)

BACKGROUND: The activity of the epidermal growth factor receptor (EGFR)-directed monoclonal antibody cetuximab combined with oxaliplatin/leucovorin/5-fluorouracil (FUFOX) was assessed in first-line metastatic gastric and oesophago-gastric junction (OGJ) cancer in a prospective phase II study showing...

Descripción completa

Detalles Bibliográficos
Autores principales: Luber, Birgit, Deplazes, Joëlle, Keller, Gisela, Walch, Axel, Rauser, Sandra, Eichmann, Martin, Langer, Rupert, Höfler, Heinz, Hegewisch-Becker, Susanna, Folprecht, Gunnar, Wöll, Ewald, Decker, Thomas, Endlicher, Esther, Lorenzen, Sylvie, Fend, Falko, Peschel, Christian, Lordick, Florian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3252322/
https://www.ncbi.nlm.nih.gov/pubmed/22152101
http://dx.doi.org/10.1186/1471-2407-11-509

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3252322/
https://www.ncbi.nlm.nih.gov/pubmed/22152101
http://dx.doi.org/10.1186/1471-2407-11-509

Ejemplares similares